Maximizing orthopedic EBITDA is the single most controllable lever available to multi-surgeon groups and PE-backed orthopedic platforms in 2026 — and the revenue cycle is where most of that control is either exercised or forfeited. Here’s what the numbers say: orthopedic practices currently command 7–10x EBITDA multiples in M&A transactions, with platform-level groups achieving the […]
Maximizing Orthopedic EBITDA with Specialty-Specific RCM









